Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Caffeine,Isometheptene Mucate,Metamizole Sodium

            Therapeutic Area: Neurology Product Name: Neosaldina

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hypera Pharma

            Deal Size: $825.0 million Upfront Cash: Undisclosed

            Deal Type: Divestment January 29, 2021

            Details:

            The divested portfolio includes select over-the-counter and prescription pharmaceutical products sold in Brazil, Mexico, and other South American, Central American and Caribbean countries, which are part of Takeda’s Growth & Emerging Markets Business Unit (GEM BU).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Edaravone

            Therapeutic Area: Neurology Product Name: Radicava

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 11, 2020

            Details:

            Soleo Health's ability to collect specific data through its proprietary SoleMetrics patient outcomes program proved valuable in helping to elucidate real-world treatment patterns with IV edaravone in the U.S.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Satralizumab-mwge

            Therapeutic Area: Neurology Product Name: Enspryng

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 09, 2020

            Details:

            Chugai Pharma Taiwan has obtained an TFDA import drug license for Chugai’s Enspryng® for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult and adolescent over 12 years old patients who are anti-aquaporin-4 (AQP4) antibody positive.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Risdiplam

            Therapeutic Area: Neurology Product Name: Evrysdi

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 16, 2020

            Details:

            The application is based on the results from two positive studies evaluating risdiplam in Types 1, 2 and 3 spinal muscular atrophy across infants and adults.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Perampanel

            Therapeutic Area: Neurology Product Name: Fycompa

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 16, 2020

            Details:

            The submission covering partial-onset seizures in pediatric patients was based on the results of a Phase III study of Fycompa as an adjunctive therapy conducted globally on pediatric patients with uncontrolled partial onset seizures/primary generalized tonic-clonic seizures.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Edaravone

            Therapeutic Area: Neurology Product Name: Radicava

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 30, 2020

            Details:

            MTPA will present details on the REFINE-ALS study, assessing RADICAVA® (edaravone), for which MTPA aims to identify and measure specific biomarkers and clinical assessments in people with ALS.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Perampanel

            Therapeutic Area: Neurology Product Name: Fycompa

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 23, 2020

            Details:

            The positive opinion is to extend the use of Fycompa as an adjunctive therapy for partial-onset seizures by expanding the approved age range from 12 years & above to 4 years & above, and for primary generalized tonic-clonic seizures from 12 years & above to 7 years & above.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Safinamide Mesylate

            Therapeutic Area: Neurology Product Name: Equfina

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eisai

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement September 07, 2020

            Details:

            Eisai will take over by transfer the manufacturing and marketing approval of Equfina from Meiji. Eisai, as the manufacturer and distributor of Equfina in Japan, will continue to provide information on the proper usage of Equfina.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Satralizumab-mwge

            Therapeutic Area: Neurology Product Name: Enspryng

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 26, 2020

            Details:

            Enspryng is the pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody created by Chugai. In Japan, the product received manufacturing and marketing approval on June 29, 2020, and was listed on the National Health Insurance (NHI) reimbursement price list today.